Physician profile
Cassandra B Mcdaniel
NPI 1629397112
$1,229.73
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $208 · 2021: $377 · 2022: $308 · 2023: $44.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $44.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $44.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $364.03 | 2019-2023 | M-M-R II, Gardasil 9, Vaxneuvance |
| Ironshore Pharmaceuticals INC. | $253.13 | 2019-2022 | |
| Kaleo, INC. | $129.62 | 2019-2022 | |
| Glaxosmithkline, LLC. | $80.01 | 2019-2022 | |
| Sanofi Pasteur INC. | $68.65 | 2019-2021 | |
| Pfizer INC. | $67.98 | 2019-2021 | |
| Adlon Therapeutics L.P. | $66.79 | 2019-2021 | |
| Cranial Technologies, INC | $48.59 | 2019-2022 | |
| Biogen, INC. | $35.93 | 2022 | |
| Sobi, INC | $24.37 | 2019 | |
| Dermira, INC. | $24.30 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $18.95 | 2021 | |
| Seqirus USA INC | $17.47 | 2022 | |
| Mylan Pharmaceuticals INC. | $17.17 | 2019 | |
| Phadia US INC. | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.